-46.2%
RBLX vs GSK
+47.2%
-93.5%
-82.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.4% | 0.0% | +1.4% | +1.4% |
| 7D | +5.1% | -3.5% | +8.6% | +5.0% |
| 30D | +28.0% | -3.4% | +31.5% | +28.0% |
| 3M | +4.6% | -8.1% | +12.7% | +4.6% |
| 6M | -24.7% | -11.1% | -13.5% | -24.7% |
| YTD | -43.8% | +0.7% | -44.6% | -43.9% |
| 1Y | -65.8% | +20.1% | -85.9% | -66.1% |
| 3Y | +59.4% | +46.1% | +13.2% | +54.1% |
| All | -46.2% | +47.2% | -93.5% | -52.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling